# EDGAR Filing Document

**Accession Number:** 0000055772
**File Stem:** 0000055772-23-000019
**Filing Date:** 2023-2
**Character Count:** 134005
**Document Hash:** 0f7cf2b027f85036ed979d36f7762aec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000055772-23-000019.hdr.sgml**: 20230207

**ACCESSION NUMBER**: 0000055772-23-000019

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 89

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230207

**DATE AS OF CHANGE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KIMBALL INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000055772
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOUSEHOLD FURNITURE [2510]
- **IRS NUMBER:** 350514506
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-03279
- **FILM NUMBER:** 23595109

**BUSINESS ADDRESS:**
- **STREET 1:** 1600 ROYAL ST
- **CITY:** JASPER
- **STATE:** IN
- **ZIP:** 47546-2256
- **BUSINESS PHONE:** 8124821600

**MAIL ADDRESS:**
- **STREET 1:** 1600 ROYAL STREET
- **CITY:** JASPER
- **STATE:** IN
- **ZIP:** 47546-2256

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JASPER CORP
- **DATE OF NAME CHANGE:** 19740826

?xml version="1.0" ? kbal-20221231

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> to <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

Commission File Number <u>0-3279</u>

![kbal-20221231_g1.jpg](kbal-20221231_g1.jpg)

---

| |
|:---|
| **KIMBALL INTERNATIONAL, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Indiana** | **35-0514506** |
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) |
| incorporation or organization) | |
| **1600 Royal Street, Jasper, Indiana** | **47546-2256** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **(812) 482-1600** |
| Registrant's telephone number, including area code |
| **Not Applicable** |
| Former name, former address and former fiscal year, if changed since last report |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<u>Title of each Class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Class B Common Stock, par value $0.05 per share | KBAL | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accelerated filer ⌧

Non-accelerated filer □&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ⌧

The number of shares outstanding of the Registrant's common stock as of January 29, 2023 was:

Class A Common Stock - 166,789 shares

Class B Common Stock - 36,245,269 shares

------

**KIMBALL INTERNATIONAL, INC.**

**FORM 10-Q**

**INDEX** 

---

| | |
|:---|:---|
| | **Page No.** |
| **PART I FINANCIAL INFORMATION** | **PART I FINANCIAL INFORMATION** |
| <u>[Item 1. Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_13)</u> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets](#ie1190e0ebebf4d3eb863d260fc7c915b_16)</u><br><u>[&nbsp;&nbsp;&nbsp;&nbsp; - December 31, 2022 (Unaudited) and June 30, 2022](#ie1190e0ebebf4d3eb863d260fc7c915b_16)</u> | <u>[3](#ie1190e0ebebf4d3eb863d260fc7c915b_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Operations (Unaudited)](#ie1190e0ebebf4d3eb863d260fc7c915b_19)</u><br><u>[&nbsp;&nbsp;&nbsp;&nbsp; -](#ie1190e0ebebf4d3eb863d260fc7c915b_19)[Three and Si](#ie1190e0ebebf4d3eb863d260fc7c915b_19)[x Months](#ie1190e0ebebf4d3eb863d260fc7c915b_19)[Ended](#ie1190e0ebebf4d3eb863d260fc7c915b_19)[December 31, 2022 and 2021](#ie1190e0ebebf4d3eb863d260fc7c915b_19)</u> | <u>[4](#ie1190e0ebebf4d3eb863d260fc7c915b_19)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)](#ie1190e0ebebf4d3eb863d260fc7c915b_22)</u><br><u>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- Three](#ie1190e0ebebf4d3eb863d260fc7c915b_22)[and Six](#ie1190e0ebebf4d3eb863d260fc7c915b_22)[Months Ended December 31, 2022 and 2021](#ie1190e0ebebf4d3eb863d260fc7c915b_22)</u> | <u>[5](#ie1190e0ebebf4d3eb863d260fc7c915b_22)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows (Unaudited)](#ie1190e0ebebf4d3eb863d260fc7c915b_25)</u><br><u>[&nbsp;&nbsp;&nbsp;&nbsp; -](#ie1190e0ebebf4d3eb863d260fc7c915b_25)[Six](#ie1190e0ebebf4d3eb863d260fc7c915b_25)[Months Ended December 31, 2022 and 2021](#ie1190e0ebebf4d3eb863d260fc7c915b_25)</u> | <u>[6](#ie1190e0ebebf4d3eb863d260fc7c915b_25)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Shareholders' Equity (Unaudited)](#ie1190e0ebebf4d3eb863d260fc7c915b_28)</u><br><u>[&nbsp;&nbsp;&nbsp;&nbsp; - Three](#ie1190e0ebebf4d3eb863d260fc7c915b_28)[and Six](#ie1190e0ebebf4d3eb863d260fc7c915b_28)[Months Ended December 31, 2022 and 2021](#ie1190e0ebebf4d3eb863d260fc7c915b_28)</u> | <u>[7](#ie1190e0ebebf4d3eb863d260fc7c915b_28)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Condensed Consolidated Financial Statements (Unaudited)](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u> | <u>[8](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u> |
| <u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#ie1190e0ebebf4d3eb863d260fc7c915b_82)</u> | <u>[21](#ie1190e0ebebf4d3eb863d260fc7c915b_82)</u> |
| <u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#ie1190e0ebebf4d3eb863d260fc7c915b_109)</u> | <u>[30](#ie1190e0ebebf4d3eb863d260fc7c915b_109)</u> |
| <u>[Item 4. Controls and Procedures](#ie1190e0ebebf4d3eb863d260fc7c915b_115)</u> | <u>[30](#ie1190e0ebebf4d3eb863d260fc7c915b_115)</u> |
| **PART II OTHER INFORMATION** | **PART II OTHER INFORMATION** |
| <u>[Item 1A. Risk Factors](#ie1190e0ebebf4d3eb863d260fc7c915b_121)</u> | <u>[30](#ie1190e0ebebf4d3eb863d260fc7c915b_121)</u> |
| <u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#ie1190e0ebebf4d3eb863d260fc7c915b_124)</u> | <u>[30](#ie1190e0ebebf4d3eb863d260fc7c915b_124)</u> |
| <u>[Item 6. Exhibits](#ie1190e0ebebf4d3eb863d260fc7c915b_127)</u> | <u>[31](#ie1190e0ebebf4d3eb863d260fc7c915b_127)</u> |
| <u>[SIGNATURES](#ie1190e0ebebf4d3eb863d260fc7c915b_130)</u> | <u>[32](#ie1190e0ebebf4d3eb863d260fc7c915b_130)</u> |

---

------

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**KIMBALL INTERNATIONAL, INC.** 

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Amounts in Thousands, Except for Share and Per Share Data)**

---

| | | |
|:---|:---|:---|
| | **(Unaudited)**<br>**December 31,<br>2022** |<br>**June 30,<br>2022** |
| **ASSETS** | | |
| Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $14067 | $10934 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net of allowances of $927 and $1,041, respectively | 60073 | 79301 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 104812 | 97969 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 15531 | 30937 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 194483 | 219141 |
| Property and equipment, net of accumulated depreciation of $189,077 and $188,530, respectively | 95609 | 96970 |
| Right-of-use operating lease assets | 13168 | 12839 |
| Goodwill | 11160 | 47844 |
| Other intangible assets, net of accumulated amortization of $51,302 and $54,553, respectively | 52563 | 54767 |
| Deferred tax assets | 16476 | 14472 |
| Other assets | 14742 | 15245 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $398201 | $461278 |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current maturities of long-term debt | $— | $33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 57249 | 70936 |
| &nbsp;&nbsp;&nbsp;&nbsp;Customer deposits | 32171 | 29706 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liability | 5709 | 6096 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends payable | 3715 | 3623 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 36739 | 41088 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 135583 | 151482 |
| Long-Term Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, less current maturities | 60000 | 68046 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term operating lease liability | 12015 | 12150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 13402 | 16064 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term liabilities | 85417 | 96260 |
| Shareholders' Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock-par value $0.05 per share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A - Shares authorized: 50,000,000<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares issued: 167,000 for both periods | 8 | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class B - Shares authorized: 100,000,000<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares issued: 42,856,000 for both periods | 2143 | 2143 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 7805 | 6304 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 233556 | 269833 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 4277 | 3766 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Treasury stock, at cost, 6,517,000 shares and 6,179,000 shares, respectively | (70588) | (68518) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Shareholders' Equity | 177201 | 213536 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Shareholders' Equity | $398201 | $461278 |

---

See <u>[Notes to Condensed Consolidated Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u>

------

**KIMBALL INTERNATIONAL, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Amounts in Thousands, Except for Per Share Data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** |
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| | **2022** | **2021** | **2022** | **2021** |
| Net Sales | $182947 | $151403 | $360758 | $308013 |
| Cost of Sales | 116810 | 104959 | 235007 | 212472 |
| Gross Profit | 66137 | 46444 | 125751 | 95541 |
| Selling and Administrative Expenses | 56795 | 51921 | 110202 | 102080 |
| Contingent Earn-out (Gain) Loss |  | (22510) | (3160) | (17900) |
| Restructuring Expense | 1679 | 1010 | 2049 | 2465 |
| Goodwill Impairment | 36684 | 34118 | 36684 | 34118 |
| Operating Income (Loss) | (29021) | (18095) | (20024) | (25222) |
| Other Income (Expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 112 | 43 | 189 | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (696) | (275) | (1377) | (532) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-operating income, net | 670 | 709 | 180 | 523 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income (expense), net | 86 | 477 | (1008) | 43 |
| Income (Loss) Before Taxes on Income | (28935) | (17618) | (21032) | (25179) |
| Provision for Income Taxes | 7128 | 3696 | 8475 | 1184 |
| Net Income (Loss) | $(36063) | $(21314) | $(29507) | $(26363) |
| Earnings (Loss) Per Share of Common Stock: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic Earnings (Loss) Per Share | $(0.99) | $(0.58) | $(0.81) | $(0.72) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings (Loss) Per Share | $(0.99) | $(0.58) | $(0.81) | $(0.72) |
| Class A and B Common Stock: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average Number of Shares Outstanding - Basic | 36539 | 36749 | 36647 | 36785 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average Number of Shares Outstanding - Diluted | 36539 | 36749 | 36647 | 36785 |

---

See <u>[Notes to Condensed Consolidated Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u>

------

**KIMBALL INTERNATIONAL, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(Amounts in Thousands)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** |
| | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** | **Three Months Ended** |
| | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **December 31, 2021** | **December 31, 2021** | **December 31, 2021** |
| **(Unaudited)** | **Pre-tax** | **Tax** | **Net of Tax** | **Pre-tax** | **Tax** | **Net of Tax** |
| Net income (loss) |  |  | $(36063) |  |  | $(21314) |
| Other comprehensive income (loss): |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Postemployment severance actuarial change | 244 | (63) | 181 | 298 | (76) | 222 |
| &nbsp;&nbsp;&nbsp;Unrealized gain (loss) on interest rate swap | 177 | (45) | 132 | 452 | (116) | 336 |
| Reclassification to (earnings) loss: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of actuarial change | (166) | 42 | (124) | (134) | 34 | (100) |
| &nbsp;&nbsp;&nbsp;Interest rate swap | (281) | 72 | (209) | 75 | (19) | 56 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | $(26) | $6 | $(20) | $691 | $(177) | $514 |
| Total comprehensive income (loss) |  |  | $(36083) |  |  | $(20800) |
|  | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)** |
|  | **Six Months Ended** | **Six Months Ended** | **Six Months Ended** | **Six Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **December 31, 2021** | **December 31, 2021** | **December 31, 2021** |
| **(Unaudited)** | **Pre-tax** | **Tax** | **Net of Tax** | **Pre-tax** | **Tax** | **Net of Tax** |
| Net income (loss) |  |  | $(29507) |  |  | $(26363) |
| Other comprehensive income (loss): |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Postemployment severance actuarial change | 373 | (96) | 277 | 563 | (145) | 418 |
| &nbsp;&nbsp;&nbsp;Unrealized gain (loss) on interest rate swap | 1065 | (274) | 791 | 101 | (26) | 75 |
| Reclassification to (earnings) loss: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of actuarial change | (332) | 85 | (247) | (270) | 69 | (201) |
| &nbsp;&nbsp;&nbsp;Interest rate swap | (417) | 107 | (310) | 133 | (34) | 99 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | $689 | $(178) | $511 | $527 | $(136) | $391 |
| Total comprehensive income (loss) |  |  | $(28996) |  |  | $(25972) |

---

See <u>[Notes to Condensed Consolidated Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u>

------

**KIMBALL INTERNATIONAL, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Amounts in Thousands)**

---

| | | |
|:---|:---|:---|
| | **(Unaudited)** | **(Unaudited)** |
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** |
| | **2022** | **2021** |
| **Cash Flows From Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $(29507) | $(26363) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash (used for) provided by operating activities: | &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash (used for) provided by operating activities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 7440 | 7185 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 4414 | 4854 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on sales of assets | (14) | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring and asset impairment charges | 1346 | 1342 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax and other deferred charges | (2166) | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment | 36684 | 34118 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 2509 | 2555 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in earn-out liability | (3160) | (17900) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (439) | (1288) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | 19201 | 5846 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (7158) | (17846) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 14530 | (1138) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (10483) | 16690 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer deposits | 2465 | 12247 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | (4129) | (7704) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 31533 | 12620 |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (9416) | (9343) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sales of assets | 337 | 124 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of capitalized software | (2126) | (2198) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 100 | 104 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used for investing activities | (11105) | (11313) |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from revolving credit facility | 86000 | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on revolving credit facility | (94000) | (10000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of long-term debt | (79) | (30) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends paid to shareholders | (6618) | (6620) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of Common Stock | (2951) | (2447) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of employee shares for tax withholding | (223) | (552) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used for financing activities | (17871) | (9649) |
| **Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash** <sup>(1)</sup> | 2557 | (8342) |
| Cash, Cash Equivalents, and Restricted Cash at Beginning of Period <sup>(1)</sup> | 11996 | 25727 |
| **Cash, Cash Equivalents, and Restricted Cash at End of Period** <sup>(1)</sup> | $14553 | $17385 |
| **Supplemental Disclosure of Cash Flow Information** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid (refunded) during the period for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | $2289 | $(149) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | $1328 | $497 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The following table reconciles cash and cash equivalents in the balance sheets to cash, cash equivalents, and restricted cash per the statements of cash flows. The restricted cash included in other assets on the balance sheet represents customer deposits held due to a foreign entity being classified as a restricted entity by a government agency subsequent to our receipt of the deposit. In addition, the restricted cash balance for periods June 30, 2022 and prior included cash held in escrow for repayment of the Payment Protection Program loan that Poppin, Inc. obtained prior to its acquisition and amounts pledged as collateral for a long-term financing arrangement as contractually required by a lender and the restriction lapsed when the related debt was paid.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Amounts in Thousands)** | **December 31,<br>2022** | **June 30,<br>2022** | **December 31,<br>2021** | **June 30,<br>2021** |
| Cash and Cash Equivalents | $14067 | $10934 | $16323 | $24336 |
| Restricted cash included in Other Assets | 486 | 1062 | 1062 | 1391 |
| Total Cash, Cash Equivalents, and Restricted Cash at end of period | $14553 | $11996 | $17385 | $25727 |

---

See <u>[Notes to Condensed Consolidated Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u>

------

**KIMBALL INTERNATIONAL, INC.** 

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY**

**(Amounts in Thousands, Except for Share and Per Share Data)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Income** | **Treasury Stock** | **Total Shareholders' Equity** |
| **Three months ended December 31, 2022 (Unaudited)** | **Class A** | **Class B** | **Additional Paid-In Capital** | **Retained Earnings** | **Accumulated Other Comprehensive Income** | **Treasury Stock** | **Total Shareholders' Equity** |
| **Amounts at September 30, 2022** | $8 | $2143 | $7283 | $272993 | $4297 | $(69353) | $217371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  | (36063) |  |  | (36063) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  | (20) |  | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of non-restricted stock (17,000 shares) |  |  | (185) |  |  | 185 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Conversion of Class A to Class B common stock (1,000 shares) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation expense related to stock compensation plans |  |  | 1341 |  |  |  | 1341 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units issuance (50,000 shares) |  |  | (634) |  |  | 472 | (162) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Common Stock (285,000 shares) |  |  |  |  |  | (1892) | (1892) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared ($0.09 per share) |  |  |  | (3374) |  |  | (3374) |
| **Amounts at December 31, 2022** | $8 | $2143 | $7805 | $233556 | $4277 | $(70588) | $177201 |
| **Three months ended December 31, 2021 (Unaudited)** |  |  |  |  |  |  |  |
| **Amounts at September 30, 2021** | $9 | $2142 | $5628 | $290618 | $1857 | $(69735) | $230519 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  | (21314) |  |  | (21314) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  | 514 |  | 514 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of non-restricted stock (9,000 shares) |  |  | (122) |  |  | 122 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Conversion of Class A to Class B common stock (7,000 shares) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation expense related to stock compensation plans |  |  | 1433 |  |  |  | 1433 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units issuance (48,000 shares) |  |  | (924) |  |  | 622 | (302) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Common Stock (72,000 shares) |  |  |  |  |  | (806) | (806) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared ($0.09 per share) |  |  |  | (3380) |  |  | (3380) |
| **Amounts at December 31, 2021** | $9 | $2142 | $6015 | $265924 | $2371 | $(69797) | $206664 |
| **Six months ended December 31, 2022 (Unaudited)** |  |  |  |  |  |  |  |
| **Amounts at June 30, 2022** | $8 | $2143 | $6304 | $269833 | $3766 | $(68518) | $213536 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  | (29507) |  |  | (29507) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  | 511 |  | 511 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of non-restricted shares (39,000 shares) |  |  | (374) |  |  | 415 | 41 |
| &nbsp;&nbsp;&nbsp;&nbsp;Conversion of Class A to Class B common stock (1,000 shares) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation expense related to stock incentive plans |  |  | 2509 |  |  |  | 2509 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units issuance (50,000 shares) |  |  | (634) |  |  | 472 | (162) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Common Stock (427,000 shares) |  |  |  |  |  | (2957) | (2957) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared ($0.18 per share) |  |  |  | (6770) |  |  | (6770) |
| **Amounts at December 31, 2022** | $8 | $2143 | $7805 | $233556 | $4277 | $(70588) | $177201 |
| **Six months ended December 31, 2021 (Unaudited)** |  |  |  |  |  |  |  |
| **Amounts at June 30, 2021** | $9 | $2142 | $5298 | $299034 | $1980 | $(68793) | $239670 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) |  |  |  | (26363) |  |  | (26363) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) |  |  |  |  | 391 |  | 391 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of non-restricted shares (18,000 shares) |  |  | (242) |  |  | 239 | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Conversion of Class A to Class B common stock (7,000 shares) |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation expense related to stock incentive plans |  |  | 2555 |  |  |  | 2555 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units issuance (78,000 shares) |  |  | (1492) |  |  | 1014 | (478) |
| &nbsp;&nbsp;&nbsp;&nbsp;Relative total shareholder return performance units issuance (5,000 shares) |  |  | (104) |  |  | 72 | (32) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Common Stock (196,000 shares) |  |  |  |  |  | (2329) | (2329) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends declared ($0.18 per share) |  |  |  | (6747) |  |  | (6747) |
| **Amounts at December 31, 2021** | $9 | $2142 | $6015 | $265924 | $2371 | $(69797) | $206664 |

---

See <u>[Notes to Condensed Consolidated Financial Statements](#ie1190e0ebebf4d3eb863d260fc7c915b_31)</u>

------

**KIMBALL INTERNATIONAL, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**Note 1. Basis of Presentation**

The accompanying unaudited Condensed Consolidated Financial Statements of Kimball International, Inc. (the "Company," "Kimball International," "we," "us," or "our") have been prepared in accordance with the instructions to Form 10-Q. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") have been condensed or omitted, although we believe that the disclosures are adequate to make the information presented not misleading. Intercompany transactions and balances have been eliminated. Management believes the financial statements include all adjustments (consisting only of normal recurring adjustments) considered necessary to present fairly the financial statements for the interim periods. The results of operations for the interim periods shown in this report are not necessarily indicative of results for any future interim period or for the entire fiscal year. It is suggested that these financial statements be read in conjunction with the financial statements and the notes thereto included in our latest annual report on Form 10-K.

***Prior Period Reclassification:***

We combined the Long-term earn-out liability line with the Other long-term liabilities line on our June 30, 2022 balance sheet as the balance no longer requires separate presentation.

**Note 2. Recent Accounting Pronouncements and Supplemental Information**

***Recently Issued Accounting Pronouncements Not Yet Adopted:***

In October 2021, the Financial Accounting Standards Board issued guidance on accounting for contract assets and contract liabilities, related to revenue contracts with customers, during a business combination by the acquiring business entity. The acquirer is to measure the contract asset and contract liability as of the acquisition date as if the acquirer had originated the contracts. This is a departure from the current practice under U.S. GAAP of recognizing contract assets and contract liabilities at fair value as of the acquisition date. The guidance will be effective in our first quarter of fiscal year 2024, though early adoption is permitted. Management is unable to predict whether the adoption of this guidance will have a material impact on our financial statements.

***Goodwill and Other Intangible Assets:***

Goodwill represents the difference between the purchase price and the related underlying tangible and intangible net asset fair values resulting from business acquisitions. Goodwill is assigned to and the fair value is tested at the reporting unit level. Annually, or if conditions indicate an earlier review is necessary, we may assess qualitative factors to determine if it is more likely than not that the fair value is less than its carrying amount. We also have the option to bypass the qualitative assessment and proceed directly to performing the quantitative goodwill impairment test which compares the carrying value of the reporting unit to the reporting unit's fair value to identify impairment. Under the quantitative assessment, if the fair value of the reporting unit is less than the carrying value, goodwill is written down to its fair value. The fair value is established primarily using a discounted cash flow analysis and secondarily a market approach utilizing current industry information. The calculation of the fair value of the reporting unit considers current market conditions existing at the assessment date and reporting unit specific scenarios weighted on probability of outcome.

Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. This analysis requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for our business, and determination of our weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit. While we have historically performed goodwill impairment testing annually during the second fiscal quarter, changes in circumstances may require interim assessments of the carrying amounts of our reporting units relative to their fair values.

In connection with our annual goodwill impairment test and the preparation of our financial statements, we assessed goodwill at the reporting unit level for impairment during our second quarter of fiscal year 2023 and based on our analysis our Poppin

------

reporting unit had a carrying amount that exceeded its fair value. Lower revenue and earnings growth projections in the Poppin reporting unit drove the decline in the fair value of the reporting unit. As a result, we recorded a goodwill impairment loss of $36.7 million during the second quarter of fiscal year 2023, as further discussed in <u>[Note 12 - Fair Value](#ie1190e0ebebf4d3eb863d260fc7c915b_67)</u> of Notes to Condensed Consolidated Statements of Operations.

---

| | | | |
|:---|:---|:---|:---|
| The changes in the carrying amount of goodwill are summarized as follows: | The changes in the carrying amount of goodwill are summarized as follows: | The changes in the carrying amount of goodwill are summarized as follows: | The changes in the carrying amount of goodwill are summarized as follows: |
| **(Amounts in Thousands)** | **Gross Goodwill** | **Accumulated Impairment** | **Net Carrying Amount** |
| June 30, 2021 | $83695 | $(1733) | $81962 |
| &nbsp;&nbsp;Additions / (Impairments) |  | (34118) | (34118) |
| June 30, 2022 | 83695 | (35851) | 47844 |
| &nbsp;&nbsp;Additions / (Impairment) |  | (36684) | (36684) |
| December 31, 2022 | $83695 | $(72535) | $11160 |

---

Other Intangible Assets reported on the Condensed Consolidated Balance Sheets consist of capitalized software, customer relationships, trade names, acquired technology, patents and trademarks, and non-compete agreements. Intangible assets are reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable over the remaining lives of the assets. As a result of the downward revision in the forecasted operations of Poppin, management identified that a triggering event had occurred, indicating that certain long-lived assets may not be recoverable. The intangible assets of the Poppin reporting unit were assessed for recoverability during the second quarter of fiscal year 2023, and the recoverability assessment indicated no impairment.

A summary of intangible assets subject to amortization is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** |
| **(Amounts in Thousands)** | **Cost** | **Accumulated<br>Amortization** | **Net Value** | **Cost** | **Accumulated<br>Amortization** | **Net Value** |
| Capitalized Software | $47841 | $36114 | $11727 | $46246 | $35521 | $10725 |
| Customer Relationships | 12000 | 4320 | 7680 | 19050 | 10518 | 8532 |
| Trade Names | 36570 | 8640 | 27930 | 36570 | 6811 | 29759 |
| Acquired Technology | 7000 | 2065 | 4935 | 7000 | 1563 | 5437 |
| Patents and Trademarks | 354 | 63 | 291 | 354 | 47 | 307 |
| Non-Compete Agreements | 100 | 100 |  | 100 | 93 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other Intangible Assets | $103865 | $51302 | $52563 | $109320 | $54553 | $54767 |

---

A summary of the useful lives of intangible assets subject to amortization is as follows:

---

| | |
|:---|:---|
| | **Years** |
| Capitalized Software | &nbsp;&nbsp;&nbsp;3 to 13 |
| Customer Relationships | &nbsp;&nbsp;&nbsp;10 |
| Trade Names | 10 |
| Acquired Technology | 7 |
| Patents | 14 |
| Trademarks | 15 |
| Non-Compete Agreements | 5 |

---

------

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: | Amortization expense incurred and future expected expenses related to intangible assets were: |
|  | **Three months ended** | **Three months ended** | **Six Months Ended** | **Six Months Ended** |  |  |  |  |  |  |
|  | **December 31** | **December 31** | **December 31** | **December 31** | **Remainder** | **Future Fiscal Years** | **Future Fiscal Years** | **Future Fiscal Years** | **Future Fiscal Years** | **Future Fiscal Years** |
| **(Amounts in Thousands)** | **2022** | **2021** | **2022** | **2021** | **2023** | **2024** | **2025** | **2026** | **2027** | **Thereafter** |
| Amortization Expense | $2219 | $2415 | $4414 | $4854 | $5186 | $9446 | $9227 | $8829 | $6481 | $13394 |

---

Capitalized software is stated at cost less accumulated amortization and is amortized using the straight-line method. During the software application development stage, capitalized costs include external consulting costs, cost of software licenses, and internal payroll and payroll-related costs for employees who are directly associated with a software project. Upgrades and enhancements are capitalized if they result in added functionality which enable the software to perform tasks it was previously incapable of performing. Software maintenance, training, data conversion, and business process re-engineering costs are expensed in the period in which they are incurred.

Trade names, non-compete agreements, acquired technology, patents and trademarks are amortized on a straight-line basis over their estimated useful lives. Customer relationships are amortized based on estimated attrition rates of customers. We have no intangible assets with indefinite useful lives which are not subject to amortization.

***Non-operating Income (Expense), net:*** 

Non-operating income and expense include the impact of such items as fair value adjustments on Supplemental Employee Retirement Plan ("SERP") investments, amortization of actuarial income, foreign currency rate movements, bank charges, and other miscellaneous non-operating income and expense items that are not directly related to operations. The gain or loss on SERP investments is offset by a change in the SERP liability that is recognized in selling and administrative expenses.

Components of the Non-operating income, net line, were:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| **(Amounts in Thousands)** | **2022** | **2021** | **2022** | **2021** |
| Gain on Supplemental Employee Retirement Plan Investments | $619 | $680 | $160 | $587 |
| Other | 51 | 29 | 20 | (64) |
| Non-operating income, net | $670 | $709 | $180 | $523 |

---

**Note 3. Restructuring**

We recognized pre-tax restructuring expense of $1.7 million and $2.0 million in the three and six months ended December 31, 2022, and recognized $1.0 million and $2.5 million for the three and six months ended December 31, 2021.

We utilized available market prices and management estimates to determine the fair value of impaired assets. Restructuring is included in the Restructuring Expense line item on our Condensed Consolidated Statements of Operations.

***Transformation Restructuring Plan:***

Current actions under our transformation restructuring plan are focused on activities such as the streamlining of manufacturing facilities, the consolidation of showrooms, and the closure of our manufacturing facility in Tijuana, Mexico which was completed during the year-to-date period of fiscal year 2023. This phase of the transformation restructuring plan began in the first quarter of our fiscal year 2021, and we expect a substantial majority of the restructuring actions to be completed by the end of fiscal year 2023.

This phase of the transformation restructuring plan is expected to generate annualized pre-tax savings of approximately $19.0 million when it is fully implemented. We currently estimate this phase of the transformation restructuring plan will incur total pre-tax restructuring charges of approximately $22.7 million to $23.3 million, with approximately $1.8 million expected to be recorded in remainder of fiscal year 2023. The restructuring charges are expected to consist of approximately $7.3 million for

------

severance and other employee-related costs, $6.0 million to $6.2 million for facility costs, and $9.4 million to $9.8 million for lease and other asset impairment. Approximately 60% of the total cost estimate is expected to be cash expense.

A summary of the charges recorded in connection with the second phase of the transformation restructuring plan is as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** | **Charges Incurred to Date** |
| | **December 31** | **December 31** | **December 31** | **December 31** | **Charges Incurred to Date** |
| **(Amounts in Thousands)** | **2022** | **2021** | **2022** | **2021** | **Charges Incurred to Date** |
| &nbsp;&nbsp;&nbsp;**Cash-related restructuring charges:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Severance and other employee related costs | $284 | $87 | $474 | $233 | $7309 |
| &nbsp;&nbsp;&nbsp;&nbsp;Facility exit costs and other cash charges | 363 | 434 | 1296 | 890 | 5244 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash-related restructuring charges | $647 | $521 | $1770 | $1123 | $12553 |
| &nbsp;&nbsp;&nbsp;**Non-cash charges:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of assets and accelerated depreciation | 1032 | 489 | 279 | 1342 | 8810 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total charges** | $1679 | $1010 | $2049 | $2465 | $21363 |

---

A summary of the current period activity in accrued restructuring related to the second phase of the transformation restructuring plan is as follows:

---

| | |
|:---|:---|
| **(Amounts in Thousands)** | **Severance and other employee related costs** |
| Balance at June 30, 2022 | $974 |
| &nbsp;&nbsp;&nbsp;Additions charged to expense | 466 |
| &nbsp;&nbsp;&nbsp;Cash payments charged against reserve | (1393) |
| &nbsp;&nbsp;&nbsp;Non-cash adjustments | (47) |
| Balance at December 31, 2022 | $— |

---

**Note 4. Revenue**

***Disaggregation of Revenue***

The following table provides information about revenue by operating segment:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| **(Amounts in Millions)** | **2022** | **2021** | **2022** | **2021** |
| Workplace & Health | $141.2 | $121.0 | $284.0 | $237.3 |
| Hospitality | 27.7 | 16.9 | 47.4 | 41.9 |
| eBusiness | 14.1 | 13.5 | 29.4 | 28.8 |
| Total Net Sales | $183.0 | $151.4 | $360.8 | $308.0 |

---

For the three and six months ended December 31, 2021, the Workplace and Health categories have been combined based on our reassessment of disaggregation of revenue based on our current method of evaluating our business.

***Contract Balances***

Receivables in the Condensed Consolidated Balance Sheets represent the amount of consideration to which we are entitled in exchange for the goods or services sold to our customers, net of allowances for doubtful accounts. Receivables are recorded when the right to consideration from the customer becomes unconditional, which is generally upon billing or upon satisfaction of a performance obligation, whichever is earlier.

------

We also receive deposits from certain customers before revenue is recognized, resulting in the recognition of a contract liability reported as Customer Deposits in the Condensed Consolidated Balance Sheets. Customer deposits are typically utilized within a year of the receipt of the deposit. The amount of revenue recognized during the six months ended December 31, 2022 that was included in the June 30, 2022 customer deposit balance was $27.5 million.

**Note 5. Leases**

Our operating lease portfolio is primarily comprised of showrooms, which expire at various dates through fiscal year 2030. We have no financing leases. Certain operating lease agreements include rental payments adjusted periodically for inflationary indices. Additionally, some leases include options to renew or terminate the leases which can be exercised at our discretion. Lease terms include the noncancellable portion of the underlying leases along with any reasonably certain lease periods associated with available renewal periods.

Certain leases have terms that are dependent upon the occurrence of events, activities, or circumstances in lease agreements and incur variable lease expense driven by warehouse square footage utilized, property taxes assessed, and other non-lease component charges. Variable lease expense is presented as operating expense in our Condensed Consolidated Statements of Operations in the same line item as expense arising from fixed lease payments for operating leases. For all classes of assets, we do not separate non-lease components of a contract from the lease components to which they relate. We do not recognize a right-of-use asset or lease liability for short-term leases that have a lease term of twelve months or less.

The components of our lease expenses are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| **(Amounts in Millions)** | **2022** | **2021** | **2022** | **2021** |
| Operating lease expense | $1.2 | $1.2 | $2.5 | $2.4 |
| Variable lease expense | 2.0 | 0.3 | 3.7 | 1.7 |
| Total lease expense | $3.2 | $1.5 | $6.2 | $4.1 |

---

Right-of-use assets for operating leases are tested for impairment in the same manner as long-lived assets used in operations as explained in <u>[Note 12 - Fair Value](#ie1190e0ebebf4d3eb863d260fc7c915b_67)</u> of Notes to Condensed Consolidated Financial Statements. During the first six months of fiscal year 2023 we had no lease impairment, however for the first six months of fiscal year 2022 we recorded $0.7 million of right-of-use asset and associated leasehold improvement impairments. The impairment charge is included in the Restructuring Expense line item on our Condensed Consolidated Statements of Operations.

Supplemental cash flow and other information related to leases are as follows:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** |
| **(Amounts in Millions)** | **2022** | **2021** |
| Cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease payments impacting lease liability | $3.2 | $3.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash impact of obtaining new right-of-use assets | $2.7 | $0.8 |
|  | **As of** | **As of** |
|  | **December 31** | **December 31** |
|  | **2022** | **2021** |
| Other information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average remaining term (in years) | 4.3 | 4.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average discount rate | 4.6% | 4.7% |

---

------

The following table summarizes the future minimum lease payments as of December 31, 2022:

---

| | |
|:---|:---|
| **(Amounts in Millions)** | **Fiscal Year Ended**<br>**June 30** <sup>(1)</sup> |
| 2023 | $3.1 |
| 2024 | 5.4 |
| 2025 | 4.0 |
| 2026 | 2.8 |
| 2027 | 2.1 |
| Thereafter | 2.1 |
| Total lease payments | $19.5 |
| Less interest | 1.8 |
| Present value of lease liabilities | $17.7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Lease payments include options to extend lease terms that are reasonably certain of being exercised. The payments exclude legally binding minimum lease payments for leases signed but not yet commenced. At December 31, 2022, we have additional operating leases that have not yet commenced for which we will record both right-of-use assets and lease liabilities of $9.6 million. The first lease is expected to commence in our third quarter of fiscal year 2023 with a term of approximately 10 years at $5.7 million, while a second lease is expected to commence in our fourth quarter of fiscal year 2023 with a lease term of approximately 12 years at $3.9 million.

**Note 6. Earnings Per Share**

Basic earnings per share are based on the weighted average number of shares outstanding during the period. Diluted earnings per share are based on the weighted average number of shares outstanding plus the assumed issuance of common shares for all potentially dilutive securities.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| **(Amounts in Thousands, Except for Per Share Data)** | **2022** | **2021** | **2022** | **2021** |
| Net Income (Loss) | $(36063) | $(21314) | $(29507) | $(26363) |
| Average Shares Outstanding for Basic EPS Calculation | 36539 | 36749 | 36647 | 36785 |
| Dilutive Effect of Average Outstanding Compensation Awards |  |  |  |  |
| Average Shares Outstanding for Diluted EPS Calculation | 36539 | 36749 | 36647 | 36785 |
| Basic Earnings (Loss) Per Share | $(0.99) | $(0.58) | $(0.81) | $(0.72) |
| Diluted Earnings (Loss) Per Share | $(0.99) | $(0.58) | $(0.81) | $(0.72) |

---

All stock compensation awards were antidilutive as a result of the net losses for the second quarters and year-to-date periods ended December 31, 2022 and December 31, 2021. For the year-to-date period ended December 31, 2022, 831,000 average restricted stock units, 131,000 average relative total shareholder return awards, and 103,000 average performance unit awards were excluded from the dilutive calculation. For the year-to-date period ended December 31, 2021, 741,000 average restricted stock units and 173,000 average relative total shareholder return awards were excluded from the dilutive calculation.

**Note 7. Income Taxes**

In determining the quarterly provision for income taxes we use an estimated annual effective tax rate which is based on expected annual income, statutory tax rates, and available tax planning opportunities in the various jurisdictions in which we operate. Unusual or infrequently occurring items are separately recognized in the quarter in which they occur. Our effective tax rates for the three and six months ended December 31, 2022 were negative tax rates of (24.6%) and (40.3%), respectively, which were lower than the combined federal and state statutory tax rates primarily due to the book versus tax treatment of nondeductible goodwill impairment, earn-out valuation adjustments, and sale of Mexican subsidiary stock. Our effective tax rates for the three

------

and six months ended December 31, 2021 were negative tax rates of (21.0%) and (4.7%), respectively, driven by the book versus tax treatment of nondeductible goodwill impairment and earn-out valuation adjustments.

**Note 8. Inventories**

Inventory components were as follows:

---

| | | |
|:---|:---|:---|
| **(Amounts in Thousands)** | **December 31,<br>2022** | **June 30,<br>2022** |
| Finished products | $74364 | $66890 |
| Work-in-process | 1581 | 1974 |
| Raw materials | 52347 | 52878 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total FIFO inventory | 128292 | 121742 |
| &nbsp;&nbsp;&nbsp;&nbsp;LIFO reserve | (23480) | (23773) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventory | $104812 | $97969 |

---

For interim reporting, LIFO inventories are computed based on quantities as of the end of the quarter and interim changes in price levels. Changes in quantities and price levels are reflected in the interim financial statements in the period in which they occur, except in cases where LIFO inventory liquidations are expected to be reinstated by fiscal year end. LIFO impact including the effect of changes in quantities, price levels, and inventory liquidations during the three and six-month periods ended December 31, 2022 were income of $0.7 million and $0.3 million, respectively and during the three and six-month periods ended December 31, 2021 were expense of $1.3 million and $3.7 million, respectively. The earnings impact of LIFO inventory liquidations during the three and six-month periods ended December 31, 2022 and December 31, 2021 were immaterial.

**Note 9. Accumulated Other Comprehensive Income**

During the three months ended December 31, 2022 and 2021, the changes in the balances of each component of Accumulated Other Comprehensive Income, net of tax, were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Accumulated Other Comprehensive Income** | | | |
| **(Amounts in Thousands)** |<br>**Postemployment Benefits Net Actuarial Gain (Loss)** |<br>**Interest Rate Swap Gain (Loss)** |<br>**Accumulated Other Comprehensive Income** |
| Balance at September 30, 2022 | $2264 | $2033 | $4297 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 181 | 132 | 313 |
| &nbsp;&nbsp;&nbsp;Reclassification to (earnings) loss | (124) | (209) | (333) |
| Net current-period other comprehensive income (loss) | 57 | (77) | (20) |
| Balance at December 31, 2022 | $2321 | $1956 | $4277 |
| Balance at September 30, 2021 | $2075 | $(218) | $1857 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 222 | 336 | 558 |
| &nbsp;&nbsp;&nbsp;Reclassification to (earnings) loss | (100) | 56 | (44) |
| Net current-period other comprehensive income (loss) | 122 | 392 | 514 |
| Balance at December 31, 2021 | $2197 | $174 | $2371 |

---

------

---

| | | | |
|:---|:---|:---|:---|
| During the six months ended December 31, 2022 and 2021, the changes in the balances of each component of Accumulated Other Comprehensive Income, net of tax, were as follows: | During the six months ended December 31, 2022 and 2021, the changes in the balances of each component of Accumulated Other Comprehensive Income, net of tax, were as follows: | During the six months ended December 31, 2022 and 2021, the changes in the balances of each component of Accumulated Other Comprehensive Income, net of tax, were as follows: | During the six months ended December 31, 2022 and 2021, the changes in the balances of each component of Accumulated Other Comprehensive Income, net of tax, were as follows: |
| **Accumulated Other Comprehensive Income** |  |  |  |
| **(Amounts in Thousands)** | **Postemployment Benefits Net Actuarial Gain (Loss)** | **Interest Rate Swap Gain (Loss)** | **Accumulated Other Comprehensive Income** |
| Balance at June 30, 2022 | $2291 | $1475 | $3766 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 277 | 791 | 1068 |
| &nbsp;&nbsp;&nbsp;Reclassification to (earnings) loss | (247) | (310) | (557) |
| Net current-period other comprehensive income (loss) | 30 | 481 | 511 |
| Balance at December 31, 2022 | $2321 | $1956 | $4277 |
| Balance at June 30, 2021 | $1980 | $— | $1980 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | 418 | 75 | 493 |
| &nbsp;&nbsp;&nbsp;Reclassification to (earnings) loss | (201) | 99 | (102) |
| Net current-period other comprehensive income (loss) | 217 | 174 | 391 |
| Balance at December 31, 2021 | $2197 | $174 | $2371 |

---

The following reclassifications were made from Accumulated Other Comprehensive Income to the Condensed Consolidated Statements of Operations:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Reclassifications from Accumulated Other Comprehensive Income** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** | **Affected Line Item in the Condensed Consolidated Statements of Operations** |
| **Reclassifications from Accumulated Other Comprehensive Income** | **December 31** | **December 31** | **December 31** | **December 31** | **Affected Line Item in the Condensed Consolidated Statements of Operations** |
| **(Amounts in Thousands)** | **2022** | **2021** | **2022** | **2021** | **Affected Line Item in the Condensed Consolidated Statements of Operations** |
| &nbsp;&nbsp;&nbsp;Postemployment Benefits Amortization of Actuarial Gain | $166 | $134 | $332 | $270 | Non-operating income (expense), net |
|  | (42) | (34) | (85) | (69) | Benefit (Provision) for Income Taxes |
|  | $124 | $100 | $247 | $201 | Net Income (Loss) |
| &nbsp;&nbsp;&nbsp;Interest Rate Swap Gain (Loss) | $281 | $(75) | $417 | $(133) | Interest expense |
|  | (72) | 19 | (107) | 34 | Benefit (Provision) for Income Taxes |
|  | $209 | $(56) | $310 | $(99) | Net Income (Loss) |
| Total Reclassifications for the Period | $333 | $44 | $557 | $102 | Net Income (Loss) |

---

Amounts in parentheses indicate reductions to income.

------

**Note 10. Long-Term Debt and Revolving Credit Facility**

Short-term borrowings and long-term debt consisted of the following obligations:

---

| | | |
|:---|:---|:---|
| **(Amounts in Thousands)** | **December 31,<br>2022** | **June 30,<br>2022** |
| Long-term debt under revolving credit facility due December 2025; 5.88% variable interest rate at December 31, 2022 | $60000 | $68000 |
| Other debt matured August 2022; 9.25% fixed interest rate |  | 79 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Debt | $60000 | $68079 |

---

As of December 31, 2022 we had a $125.0 million revolving credit facility with a maturity date of December 2025 that allowed for both issuances of letters of credit and cash borrowings. We also have an option to request an increase of the amount available for borrowing to $200.0 million, subject to participating banks' consent. The revolving loans under the Credit Agreement could consist of, at our election, advances in U.S. dollars or advances in any other currency that was agreed to by the lenders. The proceeds of the loans are to be used for general corporate purposes including acquisitions. A portion of the revolving credit facility, not to exceed $10.0 million of the principal amount, was available for the issuance of letters of credit. At December 31, 2022, we had $1.8 million in letters of credit outstanding, which reduced our borrowing capacity on the revolving credit facility. Total availability to borrow under the revolving credit facility was $63.2 million at December 31, 2022. The commitment fee on the unused portion of principal amount of the revolving credit facility is payable at a rate that ranges from 20 to 30 basis points per annum as determined by our ratio of consolidated total indebtedness to adjusted consolidated EBITDA.

During the second quarter of fiscal year 2023, we entered into a Third Amendment to Amended and Restated Credit Agreement which provides, among other items, amendments to the Credit Agreement to extend the maturity date of the Credit Facility from October 24, 2024 to December 21, 2025, and establish SOFR ("Secured Overnight Financial Rate") as a pricing benchmark for dollar borrowings in replacement of LIBOR.

We were in compliance with all debt covenants of the revolving credit facility during the six-month period ended December 31, 2022.

We have an interest rate swap agreement with a bank with a notional value of $40.0 million. The interest rate swap became effective in July 2021 and is accounted for using hedge accounting. See <u>[Note 14 - Derivative Instruments](#ie1190e0ebebf4d3eb863d260fc7c915b_76)</u> of Notes to Condensed Consolidated Statements of Operations for information regarding modification of our swap agreement which occurred during January 2023.

**Note 11. Commitments and Contingent Liabilities**

***Guarantees:***

Standby letters of credit were issued to lessors and insurance institutions and can only be drawn upon in the event of our failure to pay our obligations to a beneficiary. As of December 31, 2022, we had a maximum financial exposure from unused standby letters of credit totaling $1.8 million.

We are not aware of circumstances that would require us to perform under these arrangements and believe that the resolution of any claims that might arise in the future, either individually or in the aggregate, would not materially affect our Condensed Consolidated Financial Statements. Accordingly, no liability has been recorded as of December 31, 2022 with respect to the standby letters of credit. We also enter into commercial letters of credit to facilitate payments to vendors and from customers.

***Product Warranties:***

We provide an assurance-type warranty that guarantees our product complies with agreed-upon specifications. This warranty is not sold separately and does not convey any additional services to the customer. We estimate product warranty liability at the time of sale based on historical repair or replacement cost trends in conjunction with the length of the warranty offered. Management refines the warranty liability periodically based on changes in historical cost trends and in certain cases where specific warranty issues become known. The product warranty liability is included on the Accrued Expenses and Other lines of our Condensed Consolidated Balance Sheets.

------

Changes in the product warranty accrual for the six months ended December 31, 2022 and 2021 were as follows:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** |
| **(Amounts in Thousands)** | **2022** | **2021** |
| Product Warranty Liability at the beginning of the period | $2530 | $2861 |
| Additions to warranty accrual (including changes in estimates) | 2687 | 178 |
| Settlements made (in cash or in kind) | (2132) | (912) |
| Product Warranty Liability at the end of the period | $3085 | $2127 |

---

**Note 12. Fair Value**

We categorize assets and liabilities measured at fair value into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3: Unobservable inputs reflecting management's own assumptions about the inputs used in pricing the asset or liability.

Our policy is to recognize transfers between these levels as of the end of each quarterly reporting period. There were no transfers between these levels during the six months ended December 31, 2022 and 2021.

There were no changes in the inputs or valuation techniques used to measure fair values compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

In connection with the acquisition of Poppin, we entered into an earn-out arrangement with remaining contingent payments up to $45.0 million based on revenue and profitability milestones achieved through June 30, 2024. We do not currently expect to have any earn-out payments under this arrangement, therefore our contingent earn-out liability as of December 31, 2022 was zero. As of June 30, 2022 the fair value of the contingent earn-out liability was $3.2 million. The liability is carried at fair value and is classified in Level 3 of the fair value hierarchy and is included in Other long-term liabilities line on our Condensed Consolidated Balance Sheet. During the three and six months ended December 31, 2022, the recurring revaluation to fair value resulted in a gain of $0.0 million and $3.2 million, respectively. During the three and six months ended December 31, 2021, the recurring revaluation to fair value resulted in a gain of $22.5 million and $17.9 million, respectively.

------

***Financial Instruments Recognized at Fair Value:***

The following methods and assumptions were used to measure fair value:

---

| | | |
|:---|:---|:---|
| **<u>Financial Instrument</u>** | **<u>Level</u>** | **<u>Valuation Technique/Inputs Used</u>** |
| Cash Equivalents: Money market funds | 1 | Market - Quoted market prices |
| Trading securities: Mutual funds held in nonqualified SERP | 1 | Market - Quoted market prices |
| Derivative Assets: Stock warrants | 3 | Market - The pricing of recent purchases or sales of the investment are considered, if any, as well as positive and negative qualitative evidence, in the assessment of fair value. The value of the stock warrants fluctuates primarily in relation to the value of the privately-held company's underlying securities. |
| Derivative Asset: Interest Rate Swap | 2 | Market - Based on observable market inputs using standard calculations, such as time value, forward interest rate yield curves, and current spot rates adjusted for Kimball International's non-performance risk. |
| Contingent earn-out liability | 3 | Income - Based on a valuation model that measures the present value of the probable cash payments based upon the forecasted operating performance of the acquisition and a discount rate that captures the risk associated with the liability. |

---

***Recurring Fair Value Measurements:***

As of December 31, 2022 and June 30, 2022, the fair values of financial assets that are measured at fair value on a recurring basis using the market or income approach are categorized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** | **December 31, 2022** |
| **(Amounts in Thousands)** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** | | | | |
| Cash equivalents: Money market funds | $8308 | $— | $— | $8308 |
| Derivatives: Interest rate swap contract |  | 2635 |  | 2635 |
| Trading Securities: Mutual funds in nonqualified SERP | 10533 |  |  | 10533 |
| Derivatives: Stock warrants |  |  | 1500 | 1500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets at fair value | $18841 | $2635 | $1500 | $22976 |
|  | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** | **June 30, 2022** |
| **(Amounts in Thousands)** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Assets** |  |  |  |  |
| Cash equivalents: Money market funds | $5508 | $— | $— | $5508 |
| Derivatives: Interest rate swap contract |  | 1986 |  | 1986 |
| Trading Securities: Mutual funds in nonqualified SERP | 10517 |  |  | 10517 |
| Derivatives: Stock warrants |  |  | 1500 | 1500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets at fair value | $16025 | $1986 | $1500 | $19511 |
| **Liabilities** |  |  |  |  |
| Contingent earn-out liability |  |  | 3160 | 3160 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities at fair value | $— | $— | $3160 | $3160 |

---

------

***Non-Recurring Fair Value Measurements:***

Certain assets are measured at fair value on a non-recurring basis. These assets are not measured at fair value on an ongoing basis but are subject to fair value adjustments when events or circumstances indicate a significant adverse effect on the fair value of the asset. Assets that are written down to fair value when impaired are not subsequently adjusted to fair value unless further impairment occurs.

---

| | | |
|:---|:---|:---|
| **Non-recurring Fair Value Adjustment** | **Level** | **Valuation Technique/Inputs Used** |
| Impairment of Right of Use Lease Assets and Related Asset Groups | 3 | Income - Based on a valuation model that measures the present value of remaining lease payments less estimated sublease income at a discount rate that captures the risk associated with the future cash flows. |
| Impairment of Goodwill | 3 | Income - Based on a valuation model that determines fair value based on estimated discounted future cash flows of each reporting unit, requiring the use of significant estimates and assumptions, including revenue growth rates and EBITDA margins, future market conditions and discount rates that capture the risk associated with future cash flows. |

---

During the year-to-date period of fiscal year 2022, we recorded $0.7 million of right-of-use asset and associated leasehold improvement impairment resulting from closure from our leased Pennsylvania and Maryland facilities as part of our transformation restructuring plan. The impairment loss is included as a component of the Restructuring Expense line item on our Condensed Consolidated Statements of Operations. The asset groups used to calculate impairment included the right-of-use lease assets, leasehold improvements, and lease liabilities.

During the second quarter of fiscal years 2023 and 2022, we recorded $36.7 million and $34.1 million, respectively, of goodwill impairment related to our Poppin business. Annual goodwill testing in both years determined the carrying value of the Poppin reporting unit exceeded its relative fair value. No goodwill remains on the Poppin goodwill reporting unit.

***Financial Instruments Not Carried At Fair Value:***

Financial instruments that are not reflected in the Condensed Consolidated Balance Sheets at fair value that have carrying amounts which approximate fair value include the following:

---

| | | |
|:---|:---|:---|
| **Financial Instrument** | **Level** | **Valuation Technique/Inputs Used** |
| Notes receivable | 2 | Market - Price approximated based on the assumed collection of receivables in the normal course of business, taking into account the customer's non-performance risk. |
| Equity securities without readily determinable fair value | 3 | Cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is assessed qualitatively. |

---

The carrying value of our cash deposit accounts, trade accounts receivable, trade accounts payable, customer deposits, and dividends payable approximates fair value due to their relatively short maturity and immaterial non-performance risk. Based upon variable interest rates currently available to the Company, the fair value of our debt approximates the carrying value.

**Note 13. Investments**

***Supplemental Employee Retirement Plan Investments:***

We maintain a self-directed supplemental employee retirement plan ("SERP") in which executive employees are eligible to participate. The SERP utilizes a rabbi trust, and therefore assets in the SERP portfolio are subject to creditor claims in the event of bankruptcy. We recognize SERP investment assets on the Condensed Consolidated Balance Sheets at current fair value. A SERP liability of the same amount is recorded on the Condensed Consolidated Balance Sheets representing an obligation to distribute SERP funds to participants. The SERP investment assets are classified as trading, and accordingly, realized and unrealized gains and losses are recognized in the Other Income (Expense) section of the Condensed Consolidated Statements of Operations. Adjustments made to revalue the SERP liability are also recognized in income or expense as selling and administrative expenses

------

and offset valuation adjustments on SERP investment assets. Net unrealized holding gains (losses) for the six months ended December 31, 2022 and 2021 were, in millions, $(0.2) and $0.2, respectively.

SERP asset and liability balances were as follows:

---

| | | |
|:---|:---|:---|
| **(Amounts in Thousands)** | **December 31,<br>2022** | **June 30,<br>2022** |
| SERP investments - current asset | $3191 | $3284 |
| SERP investments - other long-term asset | 7342 | 7233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total SERP investments | $10533 | $10517 |
| SERP obligation - current liability | $3191 | $3284 |
| SERP obligation - other long-term liability | 7342 | 7233 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total SERP obligation | $10533 | $10517 |

---

***Equity securities without readily determinable fair value:***

We hold a total investment of $2.0 million in a privately-held company, including $0.5 million in equity securities without readily determinable fair value. The investment in equity securities without readily determinable fair value is included in the Other Assets line of the Condensed Consolidated Balance Sheets. See <u>[Note 12 - Fair Value](#ie1190e0ebebf4d3eb863d260fc7c915b_67)</u> of Notes to Condensed Consolidated Financial Statements for more information on the valuation of these securities. We do not hold a majority voting interest and are not the variable interest primary beneficiary of the privately-held company, thus consolidation is not required.

**Note 14. Derivative Instruments**

***Interest Rate Swap:***

We are subject to interest rate risk related to the revolving credit facility and we historically have entered into interest rate swap agreements that are based on LIBOR to manage this exposure. The interest rate swap agreements are designated as cash flow hedges that qualify for hedge accounting under the hypothetical derivative method. Fair value adjustments are recorded as a component of Accumulated Other Comprehensive Income ("AOCI"), net of tax in the Condensed Consolidated Balance Sheets. Balances in AOCI are reclassified into earnings when transactions related to the underlying risk are settled. As of December 31, 2022 we held an interest rate swap with a notional value totaling $40.0 million and a weighted average LIBOR fixed rate of 0.834%.

At December 31, 2022, our interest rate swap was recorded at fair value in current assets and non-current assets at $1.4 million and $1.2 million, respectively. At June 30, 2022, our interest rate swap was recorded in current assets and non-current assets at $0.9 million and $1.1 million, respectively.

The pre-tax balance of interest rate swap gains in AOCI as of December 31, 2022 was $2.6 million. See <u>[Note 9 - Accumulated Other Comprehensive Income](#ie1190e0ebebf4d3eb863d260fc7c915b_58)</u> of Notes to Condensed Consolidated Financial Statements for information regarding activity recorded as a component of AOCI during the three and six months ended December 31, 2022. As of December 31, 2022, we have $1.4 million of interest rate swap gains recorded in AOCI which are expected to be reclassified into earnings within the next twelve months.

Subsequent to our second quarter of fiscal year 2023, we modified our interest rate swap agreement to be based on SOFR to align with the rate in our Third Amendment to Amended and Restated Credit Agreement that we entered into during December 2022.

***Stock Warrants:***

We hold a total investment of $2.0 million in a privately-held company, including $1.5 million in stock warrants. The investment in stock warrants is accounted for as a derivative instrument and is included in the Other Assets line of the Condensed Consolidated Balance Sheets. The stock warrants are convertible into equity shares of the privately-held company upon achieving certain milestones. The value of the stock warrants will fluctuate primarily in relation to the value of the privately-held company's underlying securities, either providing an appreciation in value or potentially expiring with no value. During the quarter ended December 31, 2022, the change in fair value of the stock warrants was not significant. See <u>[Note 12 - Fair Value](#ie1190e0ebebf4d3eb863d260fc7c915b_67)</u> of Notes to Condensed Consolidated Financial Statements for more information on the valuation of these securities.

------

**Note 15. Stock Compensation**

Stock-based compensation expense during the quarter and year-to-date periods ended December 31, 2022, was $1.3 million and $2.5 million, respectively, and during the quarter and year-to-date periods ended December 31, 2021, was $1.5 million and $2.6 million, respectively. The total income tax benefit for stock compensation arrangements during the quarter and year-to-date periods ended December 31, 2022, was $0.2 million and $0.5 million, respectively, and during the quarter and year-to-date periods ended December 31, 2021, was $0.3 million and $0.6 million, respectively.

During fiscal year 2023, the following stock compensation was awarded to officers and other key employees and to members of the Board of Directors who are not employees. All awards were granted under the 2017 Stock Incentive Plan. For more information on stock compensation awards, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Type of Award** | **Quarter Awarded** | **Targeted Shares or Units** | **Grant Date Fair Value** <sup>(4)</sup> | **Grant Date Fair Value** <sup>(4)</sup> |
| Performance Units <sup>(1)</sup> | 1st Quarter | 152034 | $7.33 | $7.33 |
| Performance Units <sup>(1)</sup> | 2nd Quarter | 6160 | $6.52 | $6.52 |
| Restricted Stock Units <sup>(2)</sup> | 1st Quarter | 379087 | $7.83 | $7.83 |
| Restricted Stock Units <sup>(2)</sup> | 2nd Quarter | 10415 | $6.59 | $7.39 |
| Unrestricted Shares <sup>(3)</sup> | 1st Quarter | 21318 | $7.77 | $7.77 |
| Unrestricted Shares <sup>(3)</sup> | 2nd Quarter | 17940 | $7.41 | $7.41 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Performance units were awarded to key officers. Vesting occurs at June 30, 2025. Participants will earn from 0% to 200% of the target award depending upon the compound annual growth rate of Kimball International's adjusted earnings per share at the end of the performance period. The maximum number of units that can be issued under these awards is 316,388.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Restricted stock units were awarded to officers and key employees. Vesting occurs at June 30, 2023 and June 30, 2025. Upon vesting, the outstanding number of restricted stock units and the value of dividends accumulated over the vesting period are converted to shares of common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Unrestricted shares were awarded to non-employee members of the Board of Directors as consideration for service to Kimball International and do not have vesting periods, holding periods, restrictions on sale, or other restrictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) The grant date fair value of the performance units was based on the stock price at the date of the award, reduced by the present value of dividends normally paid over the vesting period which are not payable on outstanding performance units. The grant date fair value of the restricted stock units and unrestricted shares was based on the stock price at the date of the award.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Business Overview**

Kimball International (the "Company," "Kimball International," "we," "us," or "our") is a leading omnichannel commercial furnishings company with deep expertise in the Workplace, Health, and Hospitality markets. We combine our bold entrepreneurial spirit, a history of craftsmanship and today's design-driven thinking alongside a commitment to our culture of caring and lasting connections with our customers, shareholders, employees, and communities. For over 70 years, our brands have seized opportunities to customize solutions into personalized experiences, turning ordinary spaces into meaningful places. Our family of brands includes Kimball, National, Etc., Interwoven, Poppin, Kimball Hospitality, and D'style.

Management currently considers the following events, trends, and uncertainties to be most important to understanding our financial condition and operating performance:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Operating Environment -* While we are mindful of the challenging macroeconomic environment and heightened recessionary risks, through our focused set of strategic choices we are successfully delivering in-demand products and solutions to end markets and geographies with higher growth, resiliency and favorable return-to-office dynamics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Goodwill Impairment* - During the second quarter of fiscal year 2023 we recorded goodwill impairment of $36.7 million as the carrying value of Poppin exceeded its fair value as of the October 31, 2022 testing date. No goodwill remains on the Poppin goodwill reporting unit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Transformation Restructuring Plan* - Current actions under our transformation restructuring plan are focused on activities such as the streamlining of manufacturing facilities, the consolidation of showrooms, and the closure of our manufacturing

------

facility in Tijuana, Mexico which was completed during the first quarter of fiscal year 2023. This phase of the transformation restructuring plan began in the first quarter of our fiscal year 2021, and we expect a substantial majority of the restructuring actions to be completed by the end of fiscal year 2023. In addition to the savings already generated from the first phase of the transformation restructuring plan, the efforts of this second phase of the transformation restructuring plan are expected to generate annualized pre-tax savings of approximately $19.0 million when it is fully implemented. See <u>[Note 3 - Restructuring](#ie1190e0ebebf4d3eb863d260fc7c915b_40)</u> of Notes to Condensed Consolidated Financial Statements in Item 1 of this Form 10-Q for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Due to the contract and project nature of furniture markets, fluctuation in the demand for our products and variation in the gross margin on those projects is inherent to our business, which in turn impacts our operating results. Effective management of our manufacturing capacity is and will continue to be critical to our success. See below for further details regarding current sales and order backlog trends.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect to continue to invest in capital expenditures prudently, particularly for projects that will enhance our capabilities and diversification while providing an opportunity for growth and improved profitability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We continue to maintain a strong balance sheet. Our short-term liquidity available, represented as cash and cash equivalents plus the unused amount of our revolving credit facility, was $77.3 million at December 31, 2022.

**Financial Overview**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At or for the<br>Three Months Ended** | **At or for the<br>Three Months Ended** | | **For the**<br>**Six Months Ended** | **For the**<br>**Six Months Ended** | |
| | **December 31** | **December 31** | | **December 31** | **December 31** | |
| **(Amounts in Millions, Except for Per Share Data)** | **2022** | **2021** | **% Change** | **2022** | **2021** | **% Change** |
| Net Sales | $183 | $151.4 | 21% | $360.8 | $308 | 17% |
| Gross Profit | 66.1 | 46.4 | 42% | 125.8 | 95.5 | 32% |
| Gross Profit % | 36.2% | 30.7% |  | 34.9% | 31.0% |  |
| Selling and Administrative Expenses | 56.8 | 51.9 | 9% | 110.2 | 102.1 | 8% |
| Contingent Earn-out (Gain) Loss |  | (22.5) |  | (3.2) | (17.9) |  |
| Restructuring Expense | 1.7 | 1.0 |  | 2.0 | 2.5 |  |
| Goodwill Impairment | 36.7 | 34.1 |  | 36.7 | 34.1 |  |
| Operating Income (Loss) | (29.0) | (18.1) | (60%) | (20.0) | (25.2) | 21% |
| Operating Income (Loss) % | (15.9%) | (12.0%) |  | (5.6%) | (8.2%) |  |
| Adjusted Operating Income (Loss) \* | $11.5 | $(0.4) | 2856% | $18.7 | $0.2 | 10182% |
| Adjusted Operating Income (Loss) % \* | 6.3% | (0.3%) |  | 5.2% | 0.1% |  |
| Net Income (Loss) | $(36.1) | $(21.3) | (69%) | $(29.5) | $(26.4) | (12%) |
| Net Income (Loss) as a Percentage of Net Sales | (19.7%) | (14.1%) |  | (8.2%) | (8.6%) |  |
| Adjusted Net Income (Loss) \* | 3.0 | (5.7) | 152% | $7.8 | $(3.8) | 307% |
| Diluted Earnings (Loss) Per Share | $(0.99) | $(0.58) | (71%) | $(0.81) | $(0.72) | (13%) |
| Adjusted Diluted Earnings (Loss) Per Share\* | $0.08 | $(0.16) | 150% | $0.21 | $(0.10) | 310% |
| Return on Invested Capital \*\* | 24.9% | 0.9% |  | 22.9% | 1.5% |  |
| Adjusted EBITDA \* | $16 | $4 | 297% | $27.6 | $8.9 | 209% |
| Adjusted EBITDA % \* | 8.8% | 2.7% |  | 7.6% | 2.9% |  |
| Order Backlog \*\* | $144.8 | $196.9 | (26%) |  |  |  |

---

\* Items indicated represent Non-GAAP (Generally Accepted Accounting Principles) measurements.

\*\* Items indicated represent Key Performance Indicators.

See the "Non-GAAP Financial Measures and Other Key Performance Indicators" section below.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Net Sales by End Market** | | | | | | |
| | **Three Months Ended** | **Three Months Ended** | | **Six Months Ended** | **Six Months Ended** | |
| | **December 31** | **December 31** | | **December 31** | **December 31** | |
| **(Amounts in Millions)** | **2022** | **2021** | **% Change** | **2022** | **2021** | **% Change** |
| Workplace | $124.3 | $107.9 | 15% | $256.3 | $216.5 | 18% |
| Health | 31.0 | 26.6 | 17% | 57.1 | 49.6 | 15% |
| Hospitality | 27.7 | 16.9 | 64% | 47.4 | 41.9 | 13% |
| Total Net Sales | $183.0 | $151.4 | 21% | $360.8 | $308.0 | 17% |

---

Our Workplace end market includes sales to the commercial, financial, government, and education vertical markets and eBusiness. The revenue of Poppin is included in eBusiness.

Second quarter fiscal year 2023 consolidated net sales increased $31.6 million, or 21% compared to second quarter fiscal year 2022 net sales driven by increased pricing of workplace and health products and higher volume in our hospitality market. Consolidated net sales for the year-to-date period of fiscal year 2023 increased 17% compared to the same year-to-date period in fiscal year 2022 driven by increased pricing of workplace and health products coupled with increased sales volume of workplace products. Each of our end market sales levels can fluctuate depending on overall demand and mix of projects in a given period.

Order backlog at December 31, 2022 decreased $52.2 million, or 26%, when compared to the backlog level as of December 31, 2021 as concerns of a recession led customers to delay orders which drove declines in workplace and health order rates in the quarter ended December 31, 2022. Our manufacturing lead times have improved which allowed us to fulfill orders quicker thus also reducing our backlog. Backlog at a point in time may not be indicative of future sales trends.

Gross profit as a percent of net sales increased 550 basis points to 36.2% for the second quarter of fiscal year 2023 from 30.7% for the second quarter of fiscal year 2022. Gross profit as a percent of net sales increased 390 basis points to 34.9% for the year-to-date period of fiscal year 2023 from 31.0% for the year-to-date period of fiscal year 2022. The increased second quarter and year to date gross profit as a percent of net sales was driven by price increases, the impact of LIFO accounting which generated income during the current year compared to expense in the prior year, and savings realized from our operational excellence initiatives which more than offset inflationary pressure on materials, increased freight costs, and other manufacturing expense increases. The prior year second quarter and year to date gross profit also included the costs associated with the one-time COVID vaccine incentive which did not repeat in the current year.

Selling and administrative (S&A) expenses in the second quarter of fiscal year 2023 compared to the second quarter of fiscal year 2022 increased $4.9 million and decreased 330 basis points as a percent of net sales, due to the leverage of our increased sales. Selling and administrative expenses in the year-to-date period of fiscal year 2023 compared to the year-to-date period of fiscal year 2022 increased $8.1 million and decreased 250 basis points as a percent of net sales. Increased S&A expenses in the second quarter and year-to-date period were driven by increased incentive compensation costs, increased salary expense driven by inflation, increased advertising and marketing expense, and higher warranty expense. The prior year second quarter and year to date S&A expense also included costs associated with the one-time COVID vaccine incentive which did not repeat in the current year.

We recognized pre-tax restructuring expense of $1.7 million and $2.0 million for the three and six months ended December 31, 2022 and $1.0 million and $2.5 million for the three and six months ended December 31, 2021. See <u>[Note 3 - Restructuring](#ie1190e0ebebf4d3eb863d260fc7c915b_40)</u> of Notes to Condensed Consolidated Financial Statements in Item 1 of this Form 10-Q for additional information.

In connection with our annual goodwill impairment test, we assessed goodwill at the reporting unit level for impairment during our second quarter of fiscal year 2023 and based on our analysis determined our Poppin reporting unit had carrying value in excess of the calculated fair value. The decline in the fair value of the reporting unit was driven by revised sales and profitability forecasts primarily attributable to changes in demand due to uncertainty in the macroeconomic environment. As a result, we recorded a pre-tax, non-cash charge to reduce the carrying value of goodwill by $36.7 million during the second quarter of fiscal year 2023. During the second quarter of fiscal year 2022 we also recorded a pre-tax, non-cash charge to reduce the carrying value of goodwill by $34.1 million primarily attributable to changes in demand due to the ongoing COVID-19 pandemic and supply chain constraints. We recorded non-cash pre-tax contingent earn-out benefit during the year-to-date period of fiscal year 2023 of $3.2 million and during the second quarter and year-to-date periods of fiscal year 2022, of $22.5 million and $17.9 million,

------

respectively, which partially offset the goodwill impairment, as there is a lower likelihood of Poppin achieving targeted milestones during the earn-out period.

Other Income (Expense) consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
| **(Amounts in Thousands)** | **2022** | **2021** | **2022** | **2021** |
| Interest Income | $112 | $43 | $189 | $52 |
| Interest Expense | (696) | (275) | (1377) | (532) |
| Gain on Supplemental Employee Retirement Plan Investments | 619 | 680 | 160 | 587 |
| Other | 51 | 29 | 20 | (64) |
| Other Income (Expense), net | $86 | $477 | $(1008) | $43 |

---

Our effective tax rate for the three and six months ended December 31, 2022 were negative tax rates of (24.6%) and (40.3%) which were lower than the combined federal and state statutory tax rate primarily due to the book versus tax treatment of nondeductible goodwill impairment, earn-out valuation adjustment, and the sale of our Mexican subsidiary stock. Our effective tax rate for the three and six months ended December 31, 2021 were negative tax rates of (21.0%) and (4.7%), respectively, driven by the book versus tax treatment of nondeductible goodwill impairment and earn-out valuation adjustments.

Comparing the balance sheet as of December 31, 2022 to June 30, 2022, our accounts receivable decreased as several larger projects were finalized and the payment was received. Our prepaid expenses decline was driven by receipt of prepaid inventory in transit. As uncertainty in the macroeconomic environment is impacting customer order patterns, we revised our Poppin sales growth expectations and recognized a goodwill impairment charge which reduced our goodwill balance. Our accounts payable balance has declined as we have decelerated inventory purchases.

**Liquidity and Capital Resources** 

Our total cash and cash equivalents was $14.1 million at December 31, 2022 and $10.9 million at June 30, 2022. Our total debt was $60.0 million at December 31, 2022 and $68.1 million at June 30, 2022. During the first six months of fiscal year 2023, cash flows provided by operations of $31.5 million more than offset capital expenditures including capitalized software of $11.5 million, the return of capital to shareholders in the form of dividends which totaled $6.6 million and stock repurchases which totaled $3.0 million.

Working capital at December 31, 2022 and June 30, 2022 was $58.9 million and $67.7 million, respectively. The current ratio was 1.4 at both December 31, 2022 and June 30, 2022.

Our short-term liquidity available, represented as cash and cash equivalents plus the unused amount of our revolving credit facility, totaled $77.3 million at December 31, 2022. At December 31, 2022, we had $1.8 million in letters of credit outstanding, which reduced our borrowing capacity on the revolving credit facility. We had $60.0 million and $68.0 million of borrowings on our revolving credit facility at December 31, 2022 and June 30, 2022, respectively. Total availability to borrow under the credit facility totaled $63.2 million at December 31, 2022.

***<u>Cash Flows</u>***

The following table reflects the major categories of cash flows for the first six months of fiscal years 2023 and 2022.

---

| | | |
|:---|:---|:---|
| | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** |
| **(Amounts in Thousands)** | **2022** | **2021** |
| Net cash provided by operating activities | $31533 | $12620 |
| Net cash used for investing activities | $(11105) | $(11313) |
| Net cash used for financing activities | $(17871) | $(9649) |

---

------

*<u>Cash Flows from Operating Activities</u>*

For the first six months of fiscal year 2023 net cash provided by operating activities was $31.5 million inclusive of net loss of $29.5 million which included goodwill impairment of $36.7 million. In the first six months of fiscal year 2022 net cash provided by operating activities was $12.6 million inclusive of a net loss of $26.4 million which included $34.1 million of goodwill impairment and $17.9 million of contingent earn-out liability gains. Changes in working capital balances provided $14.4 million of cash in the first six months of fiscal year 2023 and provided $8.1 million of cash in the first six months of fiscal year 2022.

The $14.4 million of cash provided by changes in working capital balances in the first six months of fiscal year 2023 was driven by a $19.2 million decrease in receivables as several larger projects were finalized and the payment was received and a $14.5 million decrease in prepaid expenses and other current assets as prepaid in-transit inventory was received which were partially offset by a $10.5 million decline in our accounts payable as we decelerated inventory purchases.

The $8.1 million of cash provided by changes in working capital balances in the first six months of fiscal year 2022 was driven by a $17.8 million increase in inventory which was more than offset by a $16.7 million increase in our accounts payable and a $12.2 million increase in customer deposits.

Our measure of accounts receivable performance, also referred to as Days Sales Outstanding ("DSO"), for the six-month periods ended December 31, 2022 and December 31, 2021 were both 32 days. We define DSO as the average of monthly accounts and notes receivable divided by an average day's net sales. Our Production Days Supply on Hand ("PDSOH") of inventory measure for the six-month periods ended December 31, 2022 and December 31, 2021 were 98 and 69 days, respectively. The increase in PDSOH was driven by increases in average inventory levels outpacing the sales ramp up with the majority of the inventory increase related to made-to-stock inventory in our eBusiness segment. We define PDSOH as the average of the monthly net inventory divided by an average day's cost of sales.

*<u>Cash Flows from Investing Activities</u>*

During the first six months of both fiscal years 2023 and 2022, our capital investments totaled $11.5 million. The current and prior year capital investments include the construction of a warehouse, manufacturing equipment upgrades to increase automation in production facilities, software upgrades, and facility improvements.

*<u>Cash Flows from Financing Activities</u>*

During the six months ended December 31, 2022, we had proceeds from borrowings on our revolving credit facility of $86.0 million and during the same period we repaid $94.0 million on our revolving credit facility. During the six months ended December 31, 2021 we had proceeds from borrowings on our credit facility of $10.0 million and repaid $10.0 million on our revolving credit facility. We paid dividends of $6.6 million in both the six-month periods ended December 31, 2022 and December 31, 2021. Consistent with our historical dividend policy, our Board of Directors evaluates the appropriate dividend payment on a quarterly basis. We repurchased shares pursuant to a previously announced stock repurchase program, which drove cash outflow of $3.0 million and $2.4 million in the year-to-date periods of fiscal year 2023 and 2022, respectively. Future debt payments may be paid out of cash flows from operations or from future refinancing of our debt.

***<u>Revolving Credit Facility</u>***

During the second quarter of fiscal year 2023, we entered into a Third Amendment to Amended and Restated Credit Agreement which provides, among other items, amendments to the Credit Agreement to extend the maturity date of the Credit Facility from October 24, 2024 to December 21, 2025, and establish SOFR ("Secured Overnight Financing Rate") as a pricing benchmark for dollar borrowings in replacement of LIBOR. The complete amended agreement was filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 22, 2022.

As of December 31, 2022 we had a $125.0 million revolving credit facility with a maturity date of December 2025 that allowed for both issuances of letters of credit and cash borrowings. We also have an option to request an increase of the amount available for borrowing to $200.0 million, subject to participating banks' consent. The loans under the Credit Agreement could consist of, at our election, advances in U.S. dollars or advances in any other currency that was agreed to by the lenders. The proceeds are to be used for general corporate purposes including acquisitions. A portion of the revolving credit facility, not to exceed $10 million of the principal amount, was available for the issuance of letters of credit. At December 31, 2022, we had $1.8 million in letters of credit outstanding, which reduced our borrowing capacity on the revolving credit facility. At December 31, 2022 and June 30, 2022, we had $60.0 million and $68.0 million, respectively, in borrowings outstanding.

------

The revolving credit facility requires us to comply with certain debt covenants, the most significant of which is the adjusted leverage ratio and the interest coverage ratio. The adjusted leverage ratio is defined as (a) consolidated total indebtedness minus unencumbered U.S. cash equivalents in excess of $15,000,000 provided that the maximum subtraction does not exceed $35,000,000 to (b) adjusted consolidated EBITDA, determined as of the end of each of our fiscal quarters for the then most recently ended four fiscal quarters, to not be greater than 3.00 to 1.00. The interest coverage ratio, for any period, of (a) Consolidated EBITDA for such period to (b) cash interest expense for such period, calculated on a consolidated basis in accordance with GAAP for the trailing four quarter period then ending, to not be less than 3.00 to 1.00. We were in compliance with all debt covenants of the revolving credit facility during the six-month period ended December 31, 2022.

The table below compares the adjusted leverage ratio and the interest coverage ratio with the limits specified in the credit agreement.

---

| | | | |
|:---|:---|:---|:---|
|<br>**Covenant** | **At or For the Period Ended**<br>**December 31, 2022** | **Limit As Specified in**<br>**Credit Agreement** |<br>**Excess** |
| Adjusted Leverage Ratio | 1.08 | ≤ 3.00 | 1.92 |
| Interest Coverage Ratio | 10.00 | ≥ 3.00 | 7.00 |

---

***<u>Future Liquidity</u>***

We believe our principal sources of liquidity from available funds on hand, cash generated from operations, and the availability of borrowing under our revolving credit facility will be sufficient to meet our working capital and other operating needs for at least the next twelve months. Our Board of Directors declared quarterly dividends of $0.09 per share for payment during our third quarter of fiscal year 2023. Future cash dividends are subject to approval by our Board of Directors and may be adjusted as business needs or market conditions change.

During the remainder of fiscal year 2023 we expect to invest approximately $15 million in capital expenditures, particularly for projects such as machinery and equipment upgrades and automation, software, and showroom related expenses. As of December 31, 2022, there have been no material changes to our short-term and long-term contractual obligations as discussed in Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 outside the ordinary course of business. We are also assessing the potential of selling unused parcels of land. We continuously monitor for potential acquisitions that would enhance our capabilities and diversification while providing an opportunity for growth and improved profitability.

Our ability to generate cash from operations to meet our liquidity obligations could be adversely affected in the future by factors such as general economic and market conditions, lack of availability of raw material components in the supply chain, lack of availability or cost of manufacturing labor, loss of key contract customers, and other unforeseen circumstances. In particular, should demand for our products decrease significantly over the next 12 months, the available cash provided by operations could be adversely impacted.

**Non-GAAP Financial Measures and Other Key Performance Indicators**

This Management's Discussion and Analysis ("MD&A") contains non-GAAP financial measures. A non-GAAP financial measure is a numerical measure of a company's financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with U.S. GAAP in the statements of operations, statements of comprehensive income, balance sheets, statements of cash flows, or statements of shareholders' equity of the company. The non-GAAP financial measures used within this MD&A include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted operating income (loss), defined as operating income (loss) excluding restructuring expenses, goodwill impairment, market valuation adjustments related to our SERP liability, acquisition-related amortization and inventory valuation adjustments, contingent earn-out gain or loss, and COVID vaccine incentive costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted operating income (loss) percentage, defined as adjusted operating income as a percentage of net sales;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted net income (loss), defined as net income (loss) excluding restructuring expenses, goodwill impairment, acquisition-related amortization and inventory valuation adjustments, contingent earn-out gain or loss, and COVID vaccine incentive costs;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted diluted earnings (loss) per share, defined as diluted earnings (loss) per share excluding restructuring expenses, goodwill impairment, acquisition-related amortization and inventory valuation adjustments, contingent earn-out gain or loss, and COVID vaccine incentive costs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted EBITDA, defined as earnings before interest, statutory income tax impacts for taxable after-tax measures, depreciation, and amortization and excluding restructuring expenses, goodwill impairment, acquisition-related inventory valuation adjustments, contingent earn-out gain or loss, and COVID vaccine incentive costs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adjusted EBITDA percentage, defined as adjusted EBITDA as a percentage of net sales.

Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the tables below. Management believes it is useful for investors to understand and to be able to meaningfully trend, analyze and benchmark how our core operations performed without market value adjustments related to our SERP liability, without expenses incurred in executing our transformation restructuring plan, without goodwill impairment costs, without acquisition-related costs, and without COVID vaccine incentive costs. Many of our internal performance measures that management uses to make certain operating decisions exclude these expenses to enable meaningful trending of core operating metrics. These non-GAAP financial measures should not be viewed as an alternative to the GAAP measures and are presented as supplemental information.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Non-GAAP Financial Measures and Other Key Performance Indicators** | **Reconciliation of Non-GAAP Financial Measures and Other Key Performance Indicators** | | | |
| **(Amounts in Thousands, Except for Per Share Data)** | | | | |
| **Adjusted Operating Income (Loss)** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Operating Income (Loss), as reported | $(29021) | $(18095) | $(20024) | $(25222) |
| Add: Pre-tax Restructuring Expense | 1679 | 1010 | 2049 | 2465 |
| Add: Pre-tax Goodwill Impairment | 36684 | 34118 | 36684 | 34118 |
| Add: Pre-tax Expense Adjustment to SERP Liability | 619 | 680 | 160 | 587 |
| Add: Pre-tax Acquisition-related Amortization | 1502 | 1610 | 3004 | 3220 |
| Add: Pre-tax Acquisition-related Inventory Valuation Adjustment |  | 62 |  | 205 |
| Add: Pre-tax Contingent Earn-Out (Gain) Loss |  | (22510) | (3160) | (17900) |
| Add: Pre-tax COVID Vaccine Incentive |  | 2709 |  | 2709 |
| Adjusted Operating Income (Loss) | $11463 | $(416) | $18713 | $182 |
| Net Sales | $182947 | $151403 | $360758 | $308013 |
| Adjusted Operating Income (Loss) % | 6.3% | (0.3%) | 5.2% | 0.1% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Adjusted Net Income (Loss)** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net Income (Loss), as reported | $(36063) | $(21314) | $(29507) | $(26363) |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax Restructuring Expense | 1679 | 1010 | 2049 | 2465 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on Restructuring Expense | (431) | (259) | (527) | (634) |
| Add: After-tax Restructuring Expense | 1248 | 751 | 1522 | 1831 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax Goodwill Impairment | 36684 | 34118 | 36684 | 34118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on Goodwill Impairment |  |  |  |  |
| Add: After-tax Goodwill Impairment | 36684 | 34118 | 36684 | 34118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax Acquisition-related Amortization | 1502 | 1610 | 3004 | 3220 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on Acquisition-related Amortization | (386) | (414) | (773) | (829) |
| Add: After-tax Acquisition-related Amortization | 1116 | 1196 | 2231 | 2391 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax Acquisition-related Inventory Valuation Adjustment |  | 62 |  | 205 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on Acquisition-related Inventory Valuation Adjustment |  | (16) |  | (53) |
| Add: After-tax Acquisition-related Inventory Adjustment |  | 46 |  | 152 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax Contingent Earn-Out (Gain) Loss |  | (22510) | (3160) | (17900) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on Contingent Earn-Out (Gain) Loss |  |  |  |  |
| Add: After-tax Contingent Earn-Out (Gain) Loss |  | (22510) | (3160) | (17900) |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-tax COVID Vaccine Incentive |  | 2709 |  | 2709 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax on COVID Vaccine Incentive |  | (697) |  | (697) |
| Add: After-tax COVID Vaccine Incentive |  | 2012 |  | 2012 |
| Adjusted Net Income (Loss) | $2985 | $(5701) | $7770 | $(3759) |
| **Adjusted Diluted Earnings (Loss) Per Share** | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Diluted Earnings (Loss) Per Share, as reported | $(0.99) | $(0.58) | $(0.81) | $(0.72) |
| Add: After-tax Restructuring Expense | 0.04 | 0.02 | 0.05 | 0.05 |
| Add: After-tax Goodwill Impairment | 1.00 | 0.93 | 1.00 | 0.93 |
| Add: After-tax Acquisition-related Amortization | 0.03 | 0.03 | 0.06 | 0.07 |
| Add: After-tax Acquisition-related Inventory Adjustment |  |  |  | 0.01 |
| Add: After-tax Contingent Earn-Out (Gain) Loss |  | (0.61) | (0.09) | (0.49) |
| Add: COVID Vaccine Incentive |  | 0.05 |  | 0.05 |
| Adjusted Diluted Earnings (Loss) Per Share | $0.08 | $(0.16) | $0.21 | $(0.10) |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Adjusted EBITDA** | | | | |
| | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
| | **December 31** | **December 31** | **December 31** | **December 31** |
|  | **2022** | **2021** | **2022** | **2021** |
| Net Income (Loss) | $(36063) | $(21314) | $(29507) | $(26363) |
| Provision for Income Taxes | 7128 | 3696 | 8475 | 1184 |
| Income (Loss) Before Taxes on Income | (28935) | (17618) | (21032) | (25179) |
| Interest Expense | 696 | 275 | 1377 | 532 |
| Interest Income | (112) | (43) | (189) | (52) |
| Depreciation | 3806 | 3623 | 7440 | 7185 |
| Amortization | 2219 | 2415 | 4414 | 4854 |
| Pre-tax Restructuring Expense | 1679 | 1010 | 2049 | 2465 |
| Pre-Tax Goodwill Impairment | 36684 | 34118 | 36684 | 34118 |
| Pre-tax Acquisition-related Inventory Valuation Adjustment |  | 62 |  | 205 |
| Pre-tax Contingent Earn-Out (Gain) Loss |  | (22510) | (3160) | (17900) |
| Pre-tax COVID Vaccine Incentive |  | 2709 |  | 2709 |
| Adjusted EBITDA | $16037 | $4041 | $27583 | $8937 |
| Net Income (Loss) % | (19.7%) | (14.1%) | (8.2%) | (8.6%) |
| Adjusted EBITDA % | 8.8% | 2.7% | 7.6% | 2.9% |

---

The order backlog metric is a key performance indicator representing firm orders placed by our customers which have not yet been fulfilled and are expected to be recognized as revenue during future quarters. The timing of shipments can vary, but generally the backlog of orders is expected to ship within a six-month period.

Return on Invested Capital is a key performance indicator calculated as: [(Earnings Before Interest, Taxes, Amortization, Restructuring Expense, Goodwill Impairment, Acquisition-related Inventory Valuation Adjustments, Contingent Earn-out Gain or Loss, and COVID Vaccine Incentive costs) multiplied by (1 minus Effective Tax Rate)] divided by (Total Shareholders' Equity plus Net Debt). Net Debt is defined as current maturities of long-term debt plus long-term debt less cash, cash equivalents, and short-term investments.

**Critical Accounting Policies**

Our Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP. These principles require the use of estimates and assumptions that affect amounts reported and disclosed in the Condensed Consolidated Financial Statements and related notes. Actual results could differ from these estimates and assumptions. Management continually reviews the accounting policies and financial information disclosures. A summary of the more significant accounting policies that require the use of estimates and judgments in preparing the financial statements is provided in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022. During the first six months of fiscal year 2023, there were no material changes in the accounting policies and assumptions previously disclosed.

**New Accounting Standards**

See <u>[Note 2 - Recent Accounting Pronouncements and Supplemental Information](#ie1190e0ebebf4d3eb863d260fc7c915b_37)</u> of Notes to Condensed Consolidated Financial Statements in Item 1 of this Form 10-Q for information regarding New Accounting Standards.

**Forward-Looking Statements**

Certain statements contained within this document are considered forward-looking under the Private Securities Litigation Reform Act of 1995. The statements generally can be identified by the use of words or phrases, including, but not limited to "intend," "anticipate," "believe," "estimate," "project," "target," "plan," "expect," "setting up," "beginning to," "will," "should," "would," "resume," or similar statements. We caution that forward-looking statements are subject to known and unknown risks and uncertainties that may cause the Company's actual future results and performance to differ materially from expected results, including, but not limited to, the possibility that any of the anticipated benefits of the Poppin acquisition will not be realized or

------

will not be realized within the expected time period; the risk that any projections or guidance by the Company, including revenues, margins, earnings, or any other financial results are not realized; a shortage of manufacturing labor and related cost; disruptions in our supply chain and freight channels including impacts on cost and availability, adverse changes in global economic conditions; successful execution of the second phase of the Company's restructuring plan; significant reduction in customer order patterns; loss of key suppliers; relationships with strategic customers and product distributors; changes in the regulatory environment; global health concerns; the potential for impairment of goodwill; or similar unforeseen events. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the Company are contained in the Company's Form 10-K filing for the fiscal year ended June 30, 2022 and other filings with the Securities and Exchange Commission.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to market risk with respect to commodity price fluctuations for components used in the manufacture of our products, primarily related to wood and wood-related components, steel, aluminum, foam, and plastics. These components are impacted by global pricing pressures, general economic conditions, and changes in tariff rates. We strive to offset increases in the cost of these materials through supplier negotiations, global sourcing initiatives, and product re-engineering and parts standardization. We are also exposed to fluctuations in transportation costs, which vary based upon freight carrier capacity and fuel prices. Transportation costs are managed by optimizing logistics and supply chain planning.

During fiscal year 2023, we have experienced market price increases in certain commodities and transportation costs. Also, during fiscal year 2022, we entered into an interest rate swap agreement with a notional value of $40.0 million to mitigate the interest rate risk related to our variable rate borrowings on our revolving line of credit. There have been no material changes to other market risks, including foreign exchange rate risks and equity rate risk, from the information disclosed in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

**Item 4. Controls and Procedures** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Evaluation of disclosure controls and procedures.

We maintain controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2022 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

**PART II. OTHER INFORMATION** 

**Item 1A. Risk Factors**

There have been no additional material changes from the risk factors disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2022.

------

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

A share repurchase program authorized by the Board of Directors was announced on February 7, 2019. The program allows for the repurchase of up to two million shares of common stock and will remain in effect until all shares authorized have been repurchased. On December 7, 2022, the Company commenced a repurchase plan under Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended, and such plan terminates on February 1, 2023. At December 31, 2022, 1.5 million shares remained available under the repurchase program.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number<br>of Shares<br>Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs** | **Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs** |
| Month #1 (October 1-October 31, 2022) | 173252 | $6.73 | 173252 | 1629587 |
| Month #2 (November 1-November 30, 2022) | 7463 | $7.44 | 7463 | 1622124 |
| Month #3 (December 1-December 31, 2022) | 104589 | $6.41 | 104589 | 1517535 |
| Total | 285304 | $6.63 | 285304 |  |

---

**Item 6. Exhibits**

Exhibits (numbered in accordance with Item 601 of Regulation S-K)

---

| | |
|:---|:---|
| 10 | <u>[Third](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[Amendment to Amended and Restated Credit Agreement, dated as of](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[December](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[2](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[1](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[, 202](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[2](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[, among Kimball International, Inc., the lender parties thereto, JPMorgan Chase Bank, National Association, as administrative agent, and the guarantors named therein (Incorporated by reference to Exhibit 10.1 to the Company's Form 8-K filed](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[Dec](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[ember 2](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[2](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[, 202](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[2](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)[)](http://www.sec.gov/Archives/edgar/data/55772/000005577222000141/exhibit101amendedcreditfac.htm)</u> |
| 31.1 | <u>[Certification filed by Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit31112312022q2.htm)</u> |
| 31.2 | <u>[Certification filed by Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit31212312022q2.htm)</u> |
| 32.1 | <u>[Certification furnished by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit32112312022q2.htm)</u> |
| 32.2 | <u>[Certification furnished by the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit32212312022q2.htm)</u> |
| 101 | The following materials from Kimball International, Inc.'s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2022 are formatted in Inline XBRL (eXtensible Business Reporting Language) and filed electronically herewith: (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Comprehensive Income; (iv) Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Shareholders' Equity; and (vi) Notes to Condensed Consolidated Financial Statements  |
| 104 | The cover page from the Company's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022, formatted in Inline XBRL and contained in Exhibit 101 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| | KIMBALL INTERNATIONAL, INC. |
| By: | /s/ KRISTINE L. JUSTER |
|  | Kristine L. Juster<br>*Chief Executive Officer* |
|  | February 7, 2023 |
| By: | /s/ TIMOTHY J. WOLFE |
|  | Timothy J. Wolfe<br>*Chief Financial Officer* |
|  | February 7, 2023 |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kristine L. Juster, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Kimball International, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 7, 2023 | |
| | | /s/ KRISTINE L. JUSTER |
| | | KRISTINE L. JUSTER<br>Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULE 13a-14(a)/15d-14(a), AS ADOPTED PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Timothy J. Wolfe, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Kimball International, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: | February 7, 2023 | |
| | | /s/ TIMOTHY J. WOLFE |
| | | TIMOTHY J. WOLFE<br>Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Kimball International, Inc. (the "Company") on Form 10-Q for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kristine L. Juster, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | February 7, 2023 | |
| | | /s/ KRISTINE L. JUSTER |
| | | KRISTINE L. JUSTER<br>Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Kimball International, Inc. (the "Company") on Form 10-Q for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Timothy J. Wolfe, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: | February 7, 2023 | |
| | | /s/ TIMOTHY J. WOLFE |
| | | TIMOTHY J. WOLFE<br>Chief Financial Officer |

---

<br>